CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2

Stock News12-09 10:14

CMB International released a research report stating that the 2025 edition of China's basic medical insurance catalog and the first commercial insurance catalog have been announced, continuing to support innovation. The report anticipates the CXO sector may see performance recovery in the second half of the year. The firm recommends buying shares of 3SBIO (01530), GUSHENGTANG (02273), WUXI XDC (02268), GIANT BIOGENE (02367), INNOVENT BIO (01801), and SINO BIOPHARM (01177). The report noted that core innovative products from multiple companies have been included in the medical insurance catalog. CMB International believes that despite fiscal pressure on medical insurance amid macroeconomic challenges and aging populations, attention should be paid to national centralized procurement renewals. While the first commercial insurance catalog may have limited short-term impact on product sales due to the small scale of commercial insurance, the bank views the catalog as highly significant—potentially marking the beginning of expanded commercial health insurance coverage in China and the development of a diversified payment system.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120480059?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120480059","market":"hk","top_or_hot":-1,"title":"CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2","media":"Stock News","content":"<p>CMB International released a research report stating that the 2025 edition of China's basic medical insurance catalog and the first commercial insurance catalog have been announced, continuing to support innovation. The report anticipates the CXO sector may see performance recovery in the second half of the year. The firm recommends buying shares of 3SBIO (01530), GUSHENGTANG (02273), WUXI XDC (02268), GIANT BIOGENE (02367), INNOVENT BIO (01801), and SINO BIOPHARM (01177). The report noted that core innovative products from multiple companies have been included in the medical insurance catalog. CMB International believes that despite fiscal pressure on medical insurance amid macroeconomic challenges and aging populations, attention should be paid to national centralized procurement renewals. While the first commercial insurance catalog may have limited short-term impact on product sales due to the small scale of commercial insurance, the bank views the catalog as highly significant—potentially marking the beginning of expanded commercial health insurance coverage in China and the development of a diversified payment system.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-09 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CMB International released a research report stating that the 2025 edition of China's basic medical insurance catalog and the first commercial insurance catalog have been announced, continuing to support innovation. The report anticipates the CXO sector may see performance recovery in the second half of the year. The firm recommends buying shares of 3SBIO (01530), GUSHENGTANG (02273), WUXI XDC (02268), GIANT BIOGENE (02367), INNOVENT BIO (01801), and SINO BIOPHARM (01177). The report noted that core innovative products from multiple companies have been included in the medical insurance catalog. CMB International believes that despite fiscal pressure on medical insurance amid macroeconomic challenges and aging populations, attention should be paid to national centralized procurement renewals. While the first commercial insurance catalog may have limited short-term impact on product sales due to the small scale of commercial insurance, the bank views the catalog as highly significant—potentially marking the beginning of expanded commercial health insurance coverage in China and the development of a diversified payment system.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014674.SGD","symbol_name":"Nikko AM All China Equity A SGD","start_time":0,"source_url":"","article_id":"1120480059","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120480059","pubTimestamp":1765246458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CMB International released a research report stating that the 2025 edition of China's basic medical insurance catalog and the first commercial insurance catalog have been announced, continuing to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK1589":"北水核心资产","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1207":"个人用品","BK1219":"保健护理服务","BK1141":"生命科学工具和服务","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","BK1191":"制药","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","02268":"药明合联","BK1161":"生物科技","01530":"三生制药","BK1593":"医美概念股","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","CXO":"康休","02367":"巨子生物","BK1515":"抗疫概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","01177":"中国生物制药","BK1583":"高瓴概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","02273":"固生堂","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","01801":"信达生物","BK1521":"挪威政府全球养老基金持仓","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD"},"translate_title":"招银国际：2025医保目录持续支持创新预计H2 CXO板块复苏","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1,"02268":1,"01177":1,"CXO":1,"01801":1,"02273":1,"02367":1},"content_text":"CMB International released a research report stating that the 2025 edition of China's basic medical insurance catalog and the first commercial insurance catalog have been announced, continuing to support innovation. The report anticipates the CXO sector may see performance recovery in the second half of the year. The firm recommends buying shares of 3SBIO (01530), GUSHENGTANG (02273), WUXI XDC (02268), GIANT BIOGENE (02367), INNOVENT BIO (01801), and SINO BIOPHARM (01177). The report noted that core innovative products from multiple companies have been included in the medical insurance catalog. CMB International believes that despite fiscal pressure on medical insurance amid macroeconomic challenges and aging populations, attention should be paid to national centralized procurement renewals. While the first commercial insurance catalog may have limited short-term impact on product sales due to the small scale of commercial insurance, the bank views the catalog as highly significant—potentially marking the beginning of expanded commercial health insurance coverage in China and the development of a diversified payment system.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120480059","isCrawlerRequest":true}